FSNUY News and Press, Fresenius SE & Co KGaA ADR

2024-07-19 03:17:43 ET Summary Despite risks, this company's future looks promising with solid revenue growth, cost savings, and market leadership in the kidney care sector. Fresenius Medical Care has shown volatility in share price but has confirmed organic growth and better-than...

MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...

Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...

CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...

2024-05-11 12:13:54 ET More on Fresenius Medical Care Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcr...

2024-05-07 07:30:00 ET Summary Fresenius, a German healthcare company, has the potential for significant growth and a near-term turnaround. The company is in the midst of a restructuring and has met its revenue and earnings targets for 2023. Despite suspending its dividend, Fr...

2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...

2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...

2024-03-21 10:22:39 ET More on Becton, Dickinson Becton, Dickinson And Company: Growth Starts To Normalize (Rating Upgrade) Becton, Dickinson and Company 2024 Q1 - Results - Earnings Call Presentation Becton, Dickinson and Company (BDX) Q1 2024 Earnings Call Transcri...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...